Atopic Dermatitis Drugs  Market

Atopic Dermatitis Drugs Market by Drugs Class (Corticosteroids, Calcineurin Inhibitors, PDE4 Inhibitors, Biologics, and Others), Routes of Administration (Topical, Injectable, and Oral), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028.

  • Report ID: HC-1954
  • Author: Growth Market Reports
  • Rating: 4.8
  • Total Reviews: 1
  • No. Of Pages: 176
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global atopic dermatitis drugs market size is expected to expand at a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to rapid development of novel therapeutics and rising use of targeted therapies. Additionally, rising number of cases along with high population under the risk of infections presents a key aspect of the market expansion.

Atopic Dermatitis Drugs Market Key Takeaways

Atopic dermatitis (AD) is a type of eczema, which has impacted large proportion of the population around the world. It can affect anyone at any time of their lifetime but mostly children or infants are mostly affected by this health condition. However, the disorder weakens its impact with age and less number of cases is observed in old age people. The cause of the disease is unknown; however, the disease is predicted to result from genetic factors and environmental-related factors. Around 60% of patients with AD show indications in the early year and nearly 90% patients display symptoms by the age of five, as per a global health report. The person with eczema develops symptoms such as dry skin, itching, and pain on the skin of ankles, upper chest, hands, feet, neck, eyelids, wrists, inside the bend of the elbows and knees, and for infants, the face and scalp are the target sites.

One in 10 people globally are likely to suffer from eczema during their life, with high frequency in early-stage of childhood, as per the National Eczema Association. The report also suggests that 31.6 million people from the U.S. are suffering from some form of eczema. The patients suffering from eczema needs to be attentive towards allergies as the allergies can aggravate the disease conditions. According to the report of American College of Allergy, asthma & immunology children and infants are mostly affected by the atopic dermatitis, and the allergy related worsening of disease is projected to around 10 to 20% of those suffering from eczema.

The Covid-19 pandemic demonstrated some negative impact on the market as the worldwide due to shifting focus to the pandemic rapidly and leaving other healthcare burden unattended globally. Various government initiative to reduce the burden on the healthcare sector by postponing non-emergency services and nationwide lockdowns have caused to slow down the development of AD drugs. However, the world has witnessed a decline of COVID-19 cases in the second half of 2020 and relaxations on the restrictions, which present key opportunities for the market expansion.

Market Trends, Drivers, Restraints, and Opportunities

  • Initiatives taken by governments to provide more affordable and better treatment along with the existence of advantageous reimbursement policies are major factors driving the market growth.
  • Rising approval of targeted therapy drugs such as Eucrisa and Dupixent is bolstering the market expansion.
  • Introduction of new biologics, treatment methods, and development in the diagnostic kits for AD drugs manufacturing are expected to boost the market revenue.
  • Replacement of primary therapies with the availability of second-line as well as premium-priced drugs is a promising development that can propel the market.
  • High cost of the drugs and therapy in the market is proving to be a major challenge for the market in the coming future.
  • Vast scope of unserved and underdeveloped segments such as pediatric population and rarer subtypes offers ample business opportunities for the market expansion during the forecast period.

Scope of the Report

The report on the global atopic dermatitis drugs market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Atopic Dermatitis Drugs Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Drugs Class (Corticosteroids, Calcineurin Inhibitors, PDE4 Inhibitors, Biologics, and Others) and Routes of Administration (Topical, Injectable, and Oral)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Valeant Pharmaceuticals; Astellas Pharma US, Inc.; Mylan; Bayer AG; Allergan; LEO Pharma; Pfizer, Inc.; Regeneron Pharmaceutical, Inc.; and Anacor Pharmaceuticals, Inc.

Market Segment Insights

Corticosetriods segment is expected to grow at a rapid pace

Based on drugs class, the global atopic dermatitis drugs market is divided into PDE4 inhibitors, corticosteroids, calcineurin inhibitors, biologics, and others. The corticosteroids segment is expected to grow at a rapid pace owing to fact that the corticosteroids is the first-line treatment for the disease. Calcineurin inhibitors has demonstrated the chances of developing carcinogenesis and nephrotoxicity. Toxic effects, non-specificity, and development of tolerance to this drugs class proving to be a key hindrance in the growth of the segment and boost shifting to other targeted therapies.

Meanwhile, the biologics segment is expected to constitute a large share of the market during the projected period as there is high number of pipeline candidates for launch along with increasing acceptance of targeted therapy. If the severe patient has shown no response to first-line therapies, then the biologics drugs are used as second- or third-line of treatment.

Atopic Dermatitis Drugs Market By Drugs Class

Topical segment is projected to expand at a considerable CAGR

On the basis of routes of administration, the market is segmented into topical, injectable, and oral. The topical segment is projected to expand at a considerable CAGR during the forecast period owing to wide adoption of the topical type as it provides fast relief to the patients. The topical medication is widely prescribed by the doctors along with moisturizers and emollients for more effective results.

On the other hand, the injectable segment is expected to exhibit a high CAGR during the forecast period as the rising development in number of new more effective products. The oral segment is projected to hold a key market share due to its rising popularity with time as the antihistamines, antibiotics, and anti-inflammatory agents are administrated through oral routes.

Atopic Dermatitis Drugs Market By Routes of Administration

North America is anticipated to constitute a key market share

In terms of regions, the global atopic dermatitis drugs market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to constitute a key market share in the coming years due to the high awareness among the population, government initiative, and high funding from government and non-government organizations. Additionally, the rise in research activities and developments along with high number of approvals of therapy drugs is driving the regional market growth.

On the other hand, the market of Asia Pacific is anticipated to register a significant growth rate during the forecast period owing to noteworthy number of unmet needs of patients, availability of effective treatment, and high spending on healthcare among a large number of population in the region.

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Atopic Dermatitis Drugs Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Atopic Dermatitis Drugs Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Atopic Dermatitis Drugs Market - Supply Chain
  4.5. Global Atopic Dermatitis Drugs Market Forecast
     4.5.1. Atopic Dermatitis Drugs Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Atopic Dermatitis Drugs Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Atopic Dermatitis Drugs Market Absolute $ Opportunity
5. Global Atopic Dermatitis Drugs Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Atopic Dermatitis Drugs Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Atopic Dermatitis Drugs Demand Share Forecast, 2019-2026
6. North America Atopic Dermatitis Drugs Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Atopic Dermatitis Drugs Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Atopic Dermatitis Drugs Demand Share Forecast, 2019-2026
7. Latin America Atopic Dermatitis Drugs Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Atopic Dermatitis Drugs Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Atopic Dermatitis Drugs Demand Share Forecast, 2019-2026
8. Europe Atopic Dermatitis Drugs Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Atopic Dermatitis Drugs Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Atopic Dermatitis Drugs Demand Share Forecast, 2019-2026
9. Asia Pacific Atopic Dermatitis Drugs Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Atopic Dermatitis Drugs Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Atopic Dermatitis Drugs Demand Share Forecast, 2019-2026
10. Middle East & Africa Atopic Dermatitis Drugs Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Atopic Dermatitis Drugs Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Atopic Dermatitis Drugs Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Atopic Dermatitis Drugs Market: Market Share Analysis
  11.2. Atopic Dermatitis Drugs Distributors and Customers
  11.3. Atopic Dermatitis Drugs Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. Valeant Pharmaceuticals Astellas Pharma US, Inc. Mylan Bayer AG Allergan LEO Pharma  
Segments Covered in the Report
The global atopic dermatitis drugs market has been segmented on the basis of

Drugs Class
  • Corticosteroids
  • Calcineurin Inhibitors
  • PDE4 Inhibitors
  • Biologics
  • Others
Routes of Administration
  • Topical
  • Injectable
  • Oral
Regions
  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa
Key Players
  • Valeant Pharmaceuticals
  • Astellas Pharma US, Inc.
  • Mylan
  • Bayer AG
  • Allergan
  • LEO Pharma
  • Pfizer, Inc.
  • Regeneron Pharmaceutical, Inc.
  • Anacor Pharmaceuticals, Inc.

Key players competing in the global atopic dermatitis drugs market are Valeant Pharmaceuticals; Astellas Pharma US, Inc.; Mylan; Bayer AG; Allergan; LEO Pharma; Pfizer, Inc.; Regeneron Pharmaceutical, Inc.; and Anacor Pharmaceuticals, Inc.

Sanofi and Pfizer are set to top the competitive landscape by 2022, which is attributed to increase in acceptance of targeted therapies - Dupixent and Eucrisa - respectively. Both these drugs are projected to accomplish blockbuster drug position and is set to achieve highest revenue by 2022. Dupixent is undergoing investigation for treatment in pediatric patients. Various biologics such as fezakinumab, nemolizumab, tralokinumab, and lebrikizumab are in the pipeline by several major players in the market.

Atopic Dermatitis Drugs Market By Key Players

Buy Report